140 related articles for article (PubMed ID: 30456886)
21. Pediatric neurofibromatosis type 2: clinical and molecular presentation, management of vestibular schwannomas, and hearing rehabilitation.
Bonne N-; Aboukais R; Baroncini M; Hochart A; Leblond P; Broly F; Dubrulle F; Lejeune JP; Vincent C
Childs Nerv Syst; 2016 Dec; 32(12):2403-2413. PubMed ID: 27704245
[TBL] [Abstract][Full Text] [Related]
22. Surgical treatment of large vestibular schwannomas in patients with neurofibromatosis type 2: outcomes on facial nerve function and hearing preservation.
Zhao F; Wang B; Yang Z; Zhou Q; Li P; Wang X; Zhang J; Zhang J; Liu P
J Neurooncol; 2018 Jun; 138(2):417-424. PubMed ID: 29492767
[TBL] [Abstract][Full Text] [Related]
23. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.
Plotkin SR; Halpin C; McKenna MJ; Loeffler JS; Batchelor TT; Barker FG
Otol Neurotol; 2010 Sep; 31(7):1135-43. PubMed ID: 20736812
[TBL] [Abstract][Full Text] [Related]
24. Pediatric cerebellopontine angle and internal auditory canal tumors: clinical article.
Holman MA; Schmitt WR; Carlson ML; Driscoll CL; Beatty CW; Link MJ
J Neurosurg Pediatr; 2013 Oct; 12(4):317-24. PubMed ID: 23909617
[TBL] [Abstract][Full Text] [Related]
25. Trends in phenotype in the English paediatric neurofibromatosis type 2 cohort stratified by genetic severity.
Halliday D; Emmanouil B; Vassallo G; Lascelles K; Nicholson J; Chandratre S; Anand G; Wasik M; Pretorius P; Evans DG; Parry A;
Clin Genet; 2019 Aug; 96(2):151-162. PubMed ID: 30993672
[TBL] [Abstract][Full Text] [Related]
26. Audiovestibular Characteristics of Small Cochleovestibular Schwannomas in Neurofibromatosis Type 2.
Holliday MA; Kim HJ; Zalewski CK; Wafa T; Dewan R; King KA; Brewer CC; Butman JA; Asthagiri AR
Otolaryngol Head Neck Surg; 2014 Jul; 151(1):117-24. PubMed ID: 24718755
[TBL] [Abstract][Full Text] [Related]
27. Hearing optimisation in neurofibromatosis type 2: A systematic review.
Lloyd SKW; King AT; Rutherford SA; Hammerbeck-Ward CL; Freeman SRM; Mawman DJ; O'Driscoll M; Evans DG
Clin Otolaryngol; 2017 Dec; 42(6):1329-1337. PubMed ID: 28371358
[TBL] [Abstract][Full Text] [Related]
28. Neurofibromatosis Type 2-Related Eye Disease Correlated With Genetic Severity Type.
Painter SL; Sipkova Z; Emmanouil B; Halliday D; Parry A; Elston JS
J Neuroophthalmol; 2019 Mar; 39(1):44-49. PubMed ID: 29923868
[TBL] [Abstract][Full Text] [Related]
29. Natural history of vestibular schwannomas and hearing loss in NF2 patients.
Peyre M; Bernardeschi D; Sterkers O; Kalamarides M
Neurochirurgie; 2018 Nov; 64(5):342-347. PubMed ID: 26183546
[TBL] [Abstract][Full Text] [Related]
30. Hearing preservation with the middle cranial fossa approach for neurofibromatosis type 2.
Friedman RA; Goddard JC; Wilkinson EP; Schwartz MS; Slattery WH; Fayad JN; Brackmann DE
Otol Neurotol; 2011 Dec; 32(9):1530-7. PubMed ID: 21986931
[TBL] [Abstract][Full Text] [Related]
31. Long-term growth rate of vestibular schwannoma in neurofibromatosis 2: A volumetric consideration.
Picry A; Bonne NX; Ding J; Aboukais R; Lejeune JP; Baroncini M; Dubrulle F; Vincent C
Laryngoscope; 2016 Oct; 126(10):2358-62. PubMed ID: 27075822
[TBL] [Abstract][Full Text] [Related]
32. Auditory brainstem implants for neurofibromatosis type 2.
Colletti L; Shannon R; Colletti V
Curr Opin Otolaryngol Head Neck Surg; 2012 Oct; 20(5):353-7. PubMed ID: 22886036
[TBL] [Abstract][Full Text] [Related]
33. Long-term hearing outcomes following stereotactic radiosurgery for vestibular schwannoma: patterns of hearing loss and variables influencing audiometric decline.
Carlson ML; Jacob JT; Pollock BE; Neff BA; Tombers NM; Driscoll CL; Link MJ
J Neurosurg; 2013 Mar; 118(3):579-87. PubMed ID: 23101446
[TBL] [Abstract][Full Text] [Related]
34. Hearing preservation in neurofibromatosis type 2.
Slattery WH; Brackmann DE; Hitselberger W
Am J Otol; 1998 Sep; 19(5):638-43. PubMed ID: 9752973
[TBL] [Abstract][Full Text] [Related]
35. Management strategy of vestibular schwannoma in neurofibromatosis type 2.
Odat HA; Piccirillo E; Sequino G; Taibah A; Sanna M
Otol Neurotol; 2011 Sep; 32(7):1163-70. PubMed ID: 21817944
[TBL] [Abstract][Full Text] [Related]
36. Improvement in Patient-reported Hearing After Treatment With Bevacizumab in People With Neurofibromatosis Type 2.
Huang V; Bergner AL; Halpin C; Merker VL; Sheridan MR; Widemann BC; Blakeley JO; Plotkin SR
Otol Neurotol; 2018 Jun; 39(5):632-638. PubMed ID: 29649040
[TBL] [Abstract][Full Text] [Related]
37. Hearing Rehabilitation in Neurofibromatosis Type 2.
North HJD; Lloyd SKW
Adv Otorhinolaryngol; 2018; 81():93-104. PubMed ID: 29794459
[TBL] [Abstract][Full Text] [Related]
38. Progression of hearing loss after LINAC-based stereotactic radiotherapy for vestibular schwannoma is associated with cochlear dose, not with pre-treatment hearing level.
van Linge A; van Os R; Hoekstra N; Heijmen B; Stienstra L; Dallenga A; Wolbers J; Mendez Romero A
Radiat Oncol; 2018 Dec; 13(1):253. PubMed ID: 30583739
[TBL] [Abstract][Full Text] [Related]
39. Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients.
Plotkin SR; Merker VL; Muzikansky A; Barker FG; Slattery W
Otol Neurotol; 2014 Jan; 35(1):e50-6. PubMed ID: 24335938
[TBL] [Abstract][Full Text] [Related]
40. Impact of cochlear implantation on the management strategy of patients with neurofibromatosis type 2.
Tan H; Jia H; Li Y; Zhang Z; Zhu W; Cai Y; Wang Z; Wu H
Eur Arch Otorhinolaryngol; 2018 Nov; 275(11):2667-2674. PubMed ID: 30229456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
